139 related articles for article (PubMed ID: 38723281)
41. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S; Lee H; Welsh SJ; Riggs DL; Stong N; Flynt E; Thakurta A; Keats JJ; Lonial S; Bergsagel PL; Boise LH; Bahlis NJ
Blood Cancer Discov; 2024 Jan; 5(1):56-73. PubMed ID: 37934799
[TBL] [Abstract][Full Text] [Related]
42. Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma.
Zuo X; Liu D
Hematology; 2022 Dec; 27(1):1110-1121. PubMed ID: 36121114
[TBL] [Abstract][Full Text] [Related]
43. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC
Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432
[TBL] [Abstract][Full Text] [Related]
44. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
45. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
[TBL] [Abstract][Full Text] [Related]
46. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
[TBL] [Abstract][Full Text] [Related]
47. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y
Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569
[TBL] [Abstract][Full Text] [Related]
48. Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.
Karagoz K; Stokes M; Ortiz-Estévez M; Towfic F; Flynt E; Gooding S; Pierceall W; Thakurta A
Front Genet; 2022; 13():831779. PubMed ID: 35222546
[TBL] [Abstract][Full Text] [Related]
49. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
50. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
Costacurta M; He J; Thompson PE; Shortt J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
[TBL] [Abstract][Full Text] [Related]
51. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract][Full Text] [Related]
52. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.
Awwad MHS; Kriegsmann K; Plaumann J; Benn M; Hillengass J; Raab MS; Bertsch U; Munder M; Weisel K; Salwender HJ; Hänel M; Fenk R; Dürig J; Müller-Tidow C; Goldschmidt H; Hundemer M
Oncoimmunology; 2018; 7(10):e1486356. PubMed ID: 30288348
[No Abstract] [Full Text] [Related]
53. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Cho SF; Lin L; Xing L; Li Y; Wen K; Yu T; Hsieh PA; Munshi N; Wahl J; Matthes K; Friedrich M; Arvedson T; Anderson KC; Tai YT
Blood Adv; 2020 Sep; 4(17):4195-4207. PubMed ID: 32898244
[TBL] [Abstract][Full Text] [Related]
54. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
55. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
56. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.
Chanan-Khan AA; Swaika A; Paulus A; Kumar SK; Mikhael JR; Rajkumar SV; Dispenzieri A; Lacy MQ
Blood Cancer J; 2013 Sep; 3(9):e143. PubMed ID: 24013664
[TBL] [Abstract][Full Text] [Related]
57. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
58. Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q.
Park I; Phan TM; Fang J
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680233
[TBL] [Abstract][Full Text] [Related]
59. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Li S; Pal R; Monaghan SA; Schafer P; Ouyang H; Mapara M; Galson DL; Lentzsch S
Blood; 2011 May; 117(19):5157-65. PubMed ID: 21389327
[TBL] [Abstract][Full Text] [Related]
60. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Chowdhury B; Garg S; Ni W; Sattler M; Sanchez D; Meng C; Akatsu T; Stone R; Forrester W; Harrington E; Buhrlage SJ; Griffin JD; Weisberg E
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
